We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App




Fast-Growing European Market for Molecular Diagnostics

By HospiMedica staff writers
Posted on 08 Sep 2006
Molecular diagnostics is one of the fastest growing areas in the European in vitro diagnostics (IVD) market. More...
To maximize the tremendous growth potential of molecular diagnostics, market participants will need to effectively communicate with healthcare providers and keep them updated on technologic advancements as well as the availability of new tests.

According to a new report from Frost & Sullivan (Palo Alto, CA, USA), the European molecular diagnostics market earned revenues of U.S.$517.5 million in 2005, which are estimated to reach $987.5 million in 2012.

"Early diagnosis and technological superiority over immunoassays are the key factors driving the wider adoption of molecular tests in Europe,” noted AK Arun, a research associate at Frost & Sullivan. "An emphasis on enhanced patient care, better therapeutic options, and population-screening programs are boosting the uptake of tests.”

Automated and integrated molecular diagnostic solutions are improving assay performance by decreasing the complexity involved in a molecular test. Despite the relatively high price of molecular tests, the inherent benefits, including reduced labor requirements and low cost per assay, will support their adoption.

”However, market success will depend to a large extent on effective communication,” cautioned Mr. Arun. "Manufacturers will need to communicate the value of their technologies to healthcare regulators, payers, providers and patients.”

Many molecular diagnostic assays are novel in the information they provide to the physician and the patient. Therefore, creating awareness and educating healthcare providers and patients alike will be necessary both for the success of the assay and also to qualify for reimbursement.

"Molecular diagnostics companies must conduct awareness programs aimed at educating physicians on developments in pharmacogenomics and cancer diagnosis, in addition to infectious disease screening,” advised Mr. Arun. "As recommendations by physicians and cancer association groups strongly influence the adoption of molecular tests, such awareness programs will be critical to the success of manufacturers.”



Related Links:
Frost & Sullivan

Platinum Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
12-Channel ECG
CM1200B
Newborn Hearing Screener
ALGO 7i
Exam Table
PF400
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.